ELAC2
Zinc phosphodiesterase ELAC protein 2
Also known as: FLJ10530, HPC2, RNZ2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9BQ52
- Gene
- ELAC2
- Ensembl
- ENSG00000006744
- Chromosome
- 17
- Canonical length
- 826 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The protein encoded by this gene has a C-terminal domain with tRNA 3′ processing endoribonuclease activity, which catalyzes the removal of the 3' trailer from precursor tRNAs. The protein also interacts with activated Smad family member 2 (Smad2) and its nuclear partner forkhead box H1 (also known as FAST-1), and reduced expression can suppress transforming growth factor-beta induced growth arrest. Mutations in this gene result in an increased risk of prostate cancer. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2009]
Canonical amino-acid sequenceUniProt
826 residues, UniProt reviewed canonical sequence.
>Q9BQ52|ELAC2
1 MWALCSLLRS AAGRTMSQGR TISQAPARRE RPRKDPLRHL RTREKRGPSG CSGGPNTVYL
61 QVVAAGSRDS GAALYVFSEF NRYLFNCGEG VQRLMQEHKL KVARLDNIFL TRMHWSNVGG
121 LSGMILTLKE TGLPKCVLSG PPQLEKYLEA IKIFSGPLKG IELAVRPHSA PEYEDETMTV
181 YQIPIHSEQR RGKHQPWQSP ERPLSRLSPE RSSDSESNEN EPHLPHGVSQ RRGVRDSSLV
241 VAFICKLHLK RGNFLVLKAK EMGLPVGTAA IAPIIAAVKD GKSITHEGRE ILAEELCTPP
301 DPGAAFVVVE CPDESFIQPI CENATFQRYQ GKADAPVALV VHMAPASVLV DSRYQQWMER
361 FGPDTQHLVL NENCASVHNL RSHKIQTQLN LIHPDIFPLL TSFRCKKEGP TLSVPMVQGE
421 CLLKYQLRPR REWQRDAIIT CNPEEFIVEA LQLPNFQQSV QEYRRSAQDG PAPAEKRSQY
481 PEIIFLGTGS AIPMKIRNVS ATLVNISPDT SLLLDCGEGT FGQLCRHYGD QVDRVLGTLA
541 AVFVSHLHAD HHTGLPSILL QRERALASLG KPLHPLLVVA PNQLKAWLQQ YHNQCQEVLH
601 HISMIPAKCL QEGAEISSPA VERLISSLLR TCDLEEFQTC LVRHCKHAFG CALVHTSGWK
661 VVYSGDTMPC EALVRMGKDA TLLIHEATLE DGLEEEAVEK THSTTSQAIS VGMRMNAEFI
721 MLNHFSQRYA KVPLFSPNFS EKVGVAFDHM KVCFGDFPTM PKLIPPLKAL FAGDIEEMEE
781 RREKRELRQV RAALLSRELA GGLEDGEPQQ KRAHTEEPQA KKVRAQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ELAC2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.29
- Highest tissue expression
- 56 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 56 nTPM
- heart muscle: 36 nTPM
- tonsil: 35 nTPM
- tongue: 33 nTPM
- adrenal gland: 33 nTPM
- parathyroid gland: 32 nTPM
Single-cell type
- cytotrophoblasts: 76 nCPM
- epicardial cells: 66 nCPM
- migrating cytotrophoblasts: 56 nCPM
- esophageal basal cells: 50 nCPM
- esophageal suprabasal cells: 44 nCPM
- extravillous trophoblasts: 37 nCPM
Immune cell
- NK-cell: 54 nTPM
- T-reg: 54 nTPM
- myeloid DC: 49 nTPM
- non-classical monocyte: 47 nTPM
- total PBMC: 46 nTPM
- MAIT T-cell: 44 nTPM
Brain region
- white matter: 57 nTPM
- choroid plexus: 50 nTPM
- spinal cord: 48 nTPM
- medulla oblongata: 47 nTPM
- pons: 44 nTPM
- hypothalamus: 44 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about ELAC2.
Disease | AllUniProt
Conditions ELAC2 is implicated in, by any mechanism.
- Prostate cancer, hereditary, 2 (HPC2) MIM:614731
- Combined oxidative phosphorylation deficiency 17 (COXPD17) MIM:615440
Disease | GeneticClinVar
82 pathogenic / likely-pathogenic of 1,270 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Combined oxidative phosphorylation defect type 17
- Prostate cancer, hereditary, 2
- Inborn genetic diseases
- Ovarian cancer
- Prostate cancer, hereditary, 2, susceptibility to
Disease | ImmuneIEDB
Conditions an epitope on ELAC2 was assayed in.
- skin melanoma T cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.05
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.41
- DepMap mean gene effect
- -0.92
- DepMap dependency class
- common
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- 3'-tRNA processing endoribonuclease activity
- metal ion binding
- RNA binding
- RNA endonuclease activity
- tRNA-specific ribonuclease activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Ribonuclease Z/Hydroxyacylglutathione hydrolase-like
- Anti-Pycsar protein Apyc1
- tRNase Z endonuclease
- Zinc phosphodiesterase ELAC protein 2-like
- tRNase Z endonuclease
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ELAC2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ELAC2 as an antibody target. Whether an autoantibody or antibody against ELAC2 could matter depends on whether native ELAC2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ELAC2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ELAC2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...